Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifapentine plus moxifloxacin for onchocerciasis
PACTR201608001754356Phase 2Not yet recruiting
- Sponsor
- Kumasi Centre for Collaborative Research in Tropical Medicine
- Start
- Dec 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rifapentine, moxifloxacin and doxycycline in onchocerciasis (3 arms), sponsored by Kumasi Centre for Collaborative Research in Tropical Medicine. Primary endpoint: Absence of Wolbachia endobacteria in adult worms. Planned start Dec 2016; status: not yet recruiting.
02
Drugs
rifapentinemoxifloxacindoxycycline
03
Conditions
onchocerciasis
Beyond the preview
Go deeper on PACTR201608001754356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201608001754356.